Join Svar Life Science Wieslab for the highlight of the bioanalytical year in Barcelona!

Connect with our scientific leaders and business development team at Booth B21. Learn more on how we accelerate your bioanalytical service needs for your drug development projects!

Our team of bioanalytical experts are actively contributing to the development of best practices in bioanalytics by participating in the EBF community and this year we're presenting the following oral talks:

21st OF NOVEMBER

12.20-12.40 "Current and future considerations for neutralizing antibody assays"
Anna Laurén, Director Bioanalytical Services Wieslab - on behalf of EBF
Jupiter

17.00-17.20  "Preclinical immunogenicity assessment - when to include and what to include"
Anna Laurén, Director Bioanalytical Services Wieslab -  on behalf of EBF
Auditorium 

22nd OF NOVEMBER

09.40-10.00 "Design of biosimilar bioanalytical programs - assay strategy perspectives"
Janka Ryding, Director Bioanalytical Services Wieslab
Jupiter


Skärmavbild 2019-10-31 kl. 10.39.42   

    Don't miss our poster on:

    “A novel method for quantification of ADCC activity based on the use of
     engineered effector cells and a series of matching target cells.”

 

 

 

 


 

Book a meeting to learn more on how we can help with your
bioanalytical service needs, and accelerate your drug development projects!

 

Contact us

 


#ebf #ebf19 #svarlifescience #wieslab #bioanalyticalservices #laboratoryservices #ilite #cellbasedassays #cellbased #drugdevelopment #development  #innovation

Exhibitions Linkedin HT2019-18

 

20 November - 22 November 2019

Let´s talk Gene Therapy at the 2019 Immunogenicity & Bioassays Summit in Washington, DC

Join us in Washington for the exciting opportunity to learn from the Svar team; Camilla Duborn, Dr. Michael Schwenkert, Therese Segerstein and our speaker Dr Michael Tovey, as they discuss how the products we're developing and the services we offer to help address the obstacles and analytical challenges involved in Gene Therapy.  Stop by Booth 13 and join us over a Swedish Fika and get the chance to win a Swedish designer backpack!

If you'd like to know more about how our iLite® cell-based assay technology and Bioanalytical Services can help accelerate your drug development? Make sure you book a meeting in advance and don't miss our podium presentation with Dr Michael Tovey on 16th of October at 11.40am.

Contact us

We are very proud to be hosting a podium presentation on the exciting topic of "Development of an iLite® Reporter cell line for the quantification of anti-AAV neutralizing antibodies.”

INVITATION-Gene-Therapy-M-Tovey-Presentation-2019"The efficacy of adeno-associated virus (AAV) mediated gene-therapy is limited by the development of anti-AAV antibody-mediated immunity against the virus capsid proteins resulting from previous exposure, often in early childhood, to one or more AAV serotypes. The prevalence of anti-AAV antibodies in a normal population was found to be highest for AAV1 and AAV2, approximately 67 % and 72% respectively, and 38% and 47% for AAV8 and AAV9 respectively. Furthermore, due to the high degree of conservation of the amino acid sequence of the capsid proteins, anti-AAV antibodies exhibit a high degree of cross-reactivity among different AAV serotypes, and even low-titer neutralizing antibodies (NAbs) can completely neutralize the recombinant virus. Indeed, an inverse relationship between the efficacy of AAV based gene-therapy and the development of neutralizing anti-AAV antibodies has been observed in several clinical studies.

Thus, it is of considerable importance to develop sensitive and precise cell-based in vitro assays suitable for the quantification of anti-AAV Nabs in a clinical environment. Reporter assays based on the establishment of a cell line stably transfected with a luciferase reporter-gene placed under the control of a signal specific responsive chimeric promoter, provide highly sensitive and precise methods for quantifying the activity of a wide range of biologically active agents. We have shown previously that such methods also provide the basis for the establishment of highly sensitive and precise cell-based assays for the quantification of the neutralizing antibody response to numerous pharmacology active agents.

We have also shown that, normalization of reporter gene activity induced by the factor of interest, relative to the expression of an internal standardization gene renders assay results independent of cell number and provides a means for correcting for serum matrix effects.

The availability of reporter cells in a frozen, thaw & use format, obviates the need for cell culture or specialized equipment and provides a means for obtaining highly reproducible results superior to those obtained using the same cells maintained in culture. An assay for the quantification of anti-AAV neutralizing antibodies will be described that reflects the effect of anti-AAV Nabs on the expression of recombinant AAV vectors."


Join us as we explore the future of Gene Therapy and find out how we can help streamline your future projects!

#ImmunoBio19 #svarlifescience #wieslab #bioanalyticalservices #laboratoryservices #cellbasedassays #ilite #bioanalytical #drugdevelopment #genetherapy #development #innovation

 

Exhibitions Linkedin HT2019

 

15 October - 18 October 2019

Stop by Booth 61 at the FOB - European Antibody Congress

Join us in Basel for the exciting opportunity to find out how we can help streamline your future projects. The Svar sales representatives; Libby Naylor and Maria Ekerot, are available to discuss how the products Svar is developing and the services Wieslab Bioanalytical Services offer can help address the obstacles and analytical challenges involved in developing Biologics.  

Stop by Booth 61 and join us over a Swedish Fika and – take our pop quiz for a chance to win a Swedish designer backpack!

If you'd like to know more about how our iLite® cell-based assay technology and Bioanalytical Services can help accelerate your drug development? Make sure you book a meeting in advance and don't miss our poster on "How to Select and Optimize Characterization Criteria for Assay Ready Cells – A Case Study". Stop by the poster zone during the drinks reception October 16th to get a personal walk thru with our representative Libby Naylor and Maria Ekerot. 

Book a meeting

Abstract:

"Characterization of cultured cell lines for production of biologic material and cell lines used for potency applications are outlined in various guidance documents – but there is an absence of specific instructive information about the requirements for genetically modified cell lines, such as modified cell banks used for production of assay ready cells utilized for e.g. in bioassays, ADCC assays and neutralization assays in GxP applications.

Here we offer examples from 10+ years working in development, validation and production of custom genetically modified cell lines and assay ready cells used in reporter gen assays. Examples will showcase critical aspects of characterization and include lessons learned as well as recommendations on what can be considered as an appropriate level for assay read cells."


#FOB2019 #svarlifescience #wieslab #bioanalyticalservices #laboratoryservices #cellbasedassays #ilite #bioanalytical #drugdevelopment #genetherapy #development #innovation #complement 

Exhibitions Linkedin HT2019-10

15 October - 17 October 2019

This week we're attending the European Bioassays Conference in Prague

Join us there and let's explore Best Practices for the Best Potency Assays together!

We are very excited to announce that we will be hosting hosting a scientific talk at 09.45 on September 26th during the “Session 2: Hot Topics: Ready-to-Use Cells". The title of the talk is “How to Select and Optimize Characterization Criteria for Assay Ready Cells – A Case Study” presented by Karin Blume, scientist from the Svar Research and Development Team.

Abstract:
Characterization of cultured cell lines for production of biologic material and cell lines used for potency applications are outlined in various guidance documents – but there is an absence of specific instructive information about the requirements for genetically modified cell lines, such as modified cell banks used for production of assay ready cells utilized for e.g. in bioassays, ADCC assays and neutralization assays in GxP applications.

Here we offer examples from 10+ years working in development, validation and production of custom genetically modified cell lines and assay ready cells used in reporter gene assays. Examples will showcase critical aspects of characterization and include lessons learned as well as recommendations on what can be considered as an appropriate level for assay read cells.


Make sure to stop by the Svar Booth while in Prague to meet up with Therese Segerstein - Product Manager iLite, Camilla Duborn - Senior Director Sales & Global Marketing, Karin Blume - Scientist R&D and Libby Naylor - Regional Sales Manager UK.

Learn more about our exiting products and services that can help streamline your drug development and gene therapy projects!

 

Exhibitions Linkedin HT2019-4

25 September - 27 September 2019

Stop by booth 8 at the Nordic Life Science Days in Malmö this week and meet up with Michael Akoh, VP Laboratory Services and Maria Ekerot, Regional Sales Manager to learn more about how we can help streamline your drug development!

Contact us through our website or through NLSDays partnering platform and start a conversation with one of our experts. We are looking forward to meet with familiar and new faces and discuss how we can help accelerate and optimize your drug development programs.

Find us at Booth 8!

Nordic Life Science Days is the largest Nordic partnering conference dedicated to the life science industry. Since its inception in 2013, the event has nurtured a community of people from the world of life science, and created a unique place to do business. View event program here

10 September - 12 September 2019